Apollomics (APLM) Receivables - Net (2025)

Apollomics (APLM) posted quarterly Receivables - Net of $2.3 million for Q4 2025, down 67.99% on a QoQ basis from $7.2 million in Q2 2025.

Apollomics (APLM) Receivables - Net (2025) Analysis & Trends

Apollomics (APLM) has reported Receivables - Net for 1 consecutive years, with $2.3 million the latest figure, recorded in Q4 2025.

Quarterly Receivables - Net changed N/A year-over-year to $2.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.3 million (changed N/A YoY) and the FY2025 annual result came in at $2.3 million, changed N/A from the prior year.
Receivables - Net retreated to $2.3 million in Q4 2025 per APLM's latest filing, from $7.2 million in the prior quarter.
Over the last five years, Receivables - Net for APLM reached as high as $7.2 million in Q2 2025 and fell as low as $2.3 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Apollomics	2.66 Bn	2.66 Bn	-

Download Data